XtalPi Inc.

The XtalPi team is heading to Denver for ACS Fall 2024: Elevating Chemistry from August 19-22! Visit us at Booth 1712 to discover our computational chemistry services and softwares, including our proprietary XFEP, XMolGen and CSP platforms. #ACSFall2024 #computationalchemistry #crystalstructureprediction

Lots of #DrugDiscovery companies talk about using AI and robotics. Did you know that XtalPi has been using #MachineLearning and #QuantumPhysics to predict the crystal structures of small molecule drugs since our founding, in 2015? Over time, our team of expert chemists and engineers built more artificial intelligence models to discover new drug molecules and rapidly identify the best candidates. Simultaneously, we built up a proprietary automation lab system to accelerate chemical synthesis and feed our algorithms more, better data. We don't just use AI and robotics. We harness their combined power to create a uniquely powerful drug discovery ecosystem. If you want to see exactly how we do it, check out our latest video! It highlights 3 of our software platforms, which we are excited to share more about in the near future: 🔍 PatSight Enables researchers to extract & process data from a patent in < 1 hour 💡 XMolGen Empowers scientists to explore novel chemical space using Gen AI 🎯 XFEP Offers chemists efficient & accurate FEP calculations

Did you know XtalPi helped Pfizer develop the life-saving COVID treatment Paxlovid 💊? This newly released publication details how our scientists determined the most stable polymorph of nirmatrelvir. XtalPi's Contributions: ▪️Utilized our Crystal Structure Prediction (CSP) computational method to screen for and eliminate unknown anhydrate forms of nirmatrelvir (Paxlovid), ensuring the most stable solid form without compromising its properties. ▪️Used experimental and computational methods to distinguish two closely related polymorphs, Forms 1 and 4. ▪️Determined Form 1 as the stable form for development. Our approach brought Paxlovid to patients in just 17 months from the first synthesis of nirmatrelvir, showcasing our commitment to innovation and advanced computational methods. Access the Journal Here: https://hubs.ly/Q02JyRzk0

📣 We are thrilled to share that XtalPi Inc. will be a Silver Sponsor at Formulation & Delivery US 2024! Founded in 2015, XtalPi is leading the way in revolutionising life and materials sciences through their advanced AI and robotics platform. Their innovative efforts are driving intelligent and digital transformation in research and development. 🤖 Don't miss the chance to connect with industry leaders like XtalPi and explore the latest breakthroughs in the field! ➡️https://hubs.la/Q02HMCLs0 #OGFormulation #FORMDELUS2024 #DrugFormulation #Innovation #AI #Robotics #LifeSciences

Read Here: https://hubs.li/Q02Jffrk0 Discover how we demonstrate SARM1's MOA by elucidating the SARM1-inhibitor complex structure. Results: - First demonstration of SARM1’s mechanism of action (MOA) with a non-covalent small molecule inhibitor-ADPR generated by a SARM1-catalyzed base-exchange reaction - Accelerated image processing by 50% - Achieved 2.8 Å resolution, surpassing the conventional 3 Å

The XtalPi team is excited to share that one of our discovery partners, Signet Therapeutics Inc. has received IND approval from the FDA of sigx1094, which has the potential to be the world's first target therapy for diffuse gastric cancer. Read Signet's press release here: https://hubs.li/Q02HqVjb0

Read Here: https://hubs.li/Q02F_RNC0 GPX4 is an essential enzyme for cellular antioxidant defense but is notoriously difficult to target. In this case study, we reveal how we identified three novel non-covalent hit compounds with biochemical IC50 < 10µM in just 28 days. #drugdiscovery #hitidentification

We are excited to participate in British Association for Crystal Growth Annual Conference (BACG) 2024 in Loughborough from July 1-3! Visit us at Booth 7 to speak to one of our representatives and explore our multi-pronged, risk-mitigated polymorph prediction and screening capabilities. #crystalstructureprediction #polymorphselection

We are proud to announce that XtalPi has officially gone public, raising HK$896 million through our IPO! This significant milestone is just the first step in our mission to transform drug discovery with AI and automation. Nine years ago, our founders met at MIT and created a crystal structure prediction algorithm that caught the attention of some of the world's biggest pharmaceutical companies. This kickstarted an era of rapid growth for XtalPi. We now collaborate with partners around the globe to tackle their toughest drug discovery challenges using advanced computational methods and automated laboratory systems. Backed by a diverse group of global investors, we are poised to accelerate our efforts to develop cutting-edge technologies, enhance the efficiency and accuracy of drug discovery, and ultimately bring transformative treatments to patients faster and more effectively. Thank you to our incredible team, investors, and partners for your belief in our vision. Together, we are paving the way for a new era in medicine. Stay tuned for more exciting updates as we embark on this next chapter! #XtalPi #IPO #AI #Automation #DrugDiscovery #Innovation

We are heading to Future Labs Live Basel from June 26-27! Our COO, Sarah Trice, will be participating in a panel discussion on June 27 at 11:15, titled "Digitalisation, Connectivity and Industrial IoT - Is This Lab 5.0 Or Are We Missing Something?" Don't forget to visit Booth 53 to learn more about our AI and automation capabilities at XtalPi. #automation #AI #futurelabslive